SEC EDGARSEP 191 min read$TEM

Polovin Andrew sold $221K of TEM

Polovin Andrew (EVP, Chief Legal Officer) sold 2,951 shares of Tempus AI, Inc. (TEM) at $75.00 ($0.22M total) on 2026-09-17 under a Rule 10b5-1 trading plan.

Original reporting

SEC EDGAR · Polovin Andrew

Published Sep 19, 2026, 1:15 AM UTC

Analysis

AlphAI AI DeskAI-generated

Added to AlphAI Sep 19, 2026, 1:35 AM UTC. Informational, not investment advice.

How this was made

AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About AlphAI AI Desk Scoring methodology Report an issue

AlphAI market briefInsider activity

Primary signal

$TEM

Neutral

medium confidence

Mentioned

$TEM

Relevance

3/10

AlphAI data visualization · based on SEC EDGAR

Decision brief

The 30-second read

$TEMNeutralLow

Why it matters

Form 4 filing provides the first public disclosure of this insider transaction.

Market read

The filing is a routine insider sale; traders may note it but it is unlikely to drive significant price movement.

What to watch

Potential upcoming legal or regulatory developments not disclosed.

Relevance 3/10Novelty 4/10Timing: post‑market filing on Sep 18 2026

Background

Tempus AI, Inc. (TEM) is a AI‑driven healthcare data platform listed on NASDAQ.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$TEMNeutralMedium confidence

Context

EVP and Chief Legal Officer Andrew Polovin sold 2,951 shares for $221,325 via a 10b5‑1 plan.

Expected impact

Potential short‑term dip of 0.5‑1% as market digests the sale.

Evidence & confidence

Sale amount is under $250k and represents a small fraction of holdings; impact likely limited.

Market effects

Sector

No broader sector impact; insider sale is company‑specific.

Regional

Limited to US investors tracking Tempus AI.

Global

Minimal global relevance.

Counterpoint

What could challenge this read

The sale could be routine under a pre‑arranged plan, not a bearish signal.

Key entities

Officer
Andrew Polovin
EVP, Chief Legal Officer of Tempus AI.
Company
Tempus AI, Inc.
Provider of AI‑enabled clinical data solutions.

Read at source ← All news

SEP 17

$TEMMedAI 8/10

TEM Stock Jumps As Tempus AI Joins Profitable AI Health Elite

Tempus AI Inc. (NASDAQ: TEM) shares rose 14.38% on September 17, 2026, driven by strong Q2 2026 results. Revenue grew 22% YoY to $382.5M, with net income and EBITDA turning positive at $5.6M and $45M, respectively. Gross margin is 73.5%. The company plans to acquire Personalis, funded by $816M in cash and investments, despite $1.36B in long-term debt. TEM's stock has surged from $62 to $80, attracting momentum traders.

timothysykes.com3 min

SEP 17

$TEMMed

Tempus AI Is Ripping 30% Higher This Week After Morgan Stanley Boosts Revenue Outlook

Tempus AI (TEM) shares surged 29.98% this week after Morgan Stanley highlighted new reimbursement-driven revenue growth. CEO Eric Lefkofsky estimated xT pricing could add $80M-$100M in 2025, and xF approval $250M-$300M annually. Q2 revenue was $382.49M, up 21.6% YoY, with full-year guidance raised to $1.595B-$1.605B. Analysts revised FY2027 EPS estimates positively, with a consensus revenue estimate of $1.97B.

247wallst.com2 min

SEP 15

$TEMHighAI 8/10

Tempus AI (TEM) Jumps As Upgrade, Acquisition Fuel Bullish Momentum

Tempus AI Inc. (TEM) shares rose 6.62% after Piper Sandler upgraded it to Overweight with a $76 price target. The company reported Q2 2026 revenue of $382.5M, up 22% YoY, and turned profitable. TEM is acquiring Personalis for $1.5B to expand its tumor-sequencing platform. The stock trades near $66.33, with strong cash position and improving margins.

stockstotrade.com3 min

SEP 5

$MRNAHighAI 9/10

Personalized Cancer Vaccine Breakthrough Ignites Sequencing Sector, Tempus AI's Personalis Bid Faces Rivalry Speculation — BigGo Finance

Moderna and Merck's personalized mRNA cancer vaccine (mRNA-4157) met its primary endpoint in Phase 3 trials, boosting their market value by over $50 billion. The success highlights the role of sequencing companies like Tempus AI and Personalis, which provide genetic profiling for personalized vaccines. Tempus AI's planned acquisition of Personalis faces competition as Personalis' stock surpasses the offer price, sparking speculation of a bidding war. The deal's strategic value lies in Personalis

finance.biggo.com4 min

SEP 2

$TEMHighAI 9/10

Tempus AI gets FDA clearance for pulmonary hypertension AI tool

Tempus AI (NASDAQ: TEM) received FDA clearance for its AI tool, Tempus ECG-PH, which analyzes ECGs for pulmonary hypertension. This is the third FDA-cleared device in its cardiovascular portfolio. Tempus shares rose 5.09% to $70.04, driven by positive Phase 3 trial results from Moderna and Merck, which validate the $1.5 billion acquisition of Personalis.

scanx.trade3 min